NOT-DA-21-048: Notice of Correction to Application Types Allowed for RFA-DA-22-021, "Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42

Notice of Correction to Application Types Allowed for RFA-DA-22-021, "Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed)"

Notice Number:

NOT-DA-21-048

Key Dates

Release Date:

July 7, 2021

Related Announcements

RFA-DA-22-021 - Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to change the Application Types Allowed for RFA-DA-22-021, "Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed)".

The following section has been modified:

Section II. Award Information

Currently reads:

Application Types Allowed

New (Phase I), New (Fast-Track), New (SBIR Direct Phase II)

Should correctly read:

Application Types Allowed

New (Phase I), New (Fast-Track)

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Ram Arudchandran, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-6889
Email: [email protected]

Christopher Conrad, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-496-2053
Email: [email protected]